X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
certolizumab pegol (939) 939
humans (835) 835
index medicus (834) 834
infliximab (504) 504
adalimumab (448) 448
tumor necrosis factor-alpha - antagonists & inhibitors (399) 399
gastroenterology & hepatology (359) 359
crohn's disease (343) 343
female (341) 341
treatment outcome (297) 297
male (293) 293
crohn disease - drug therapy (291) 291
antibodies, monoclonal - therapeutic use (273) 273
adult (269) 269
inflammatory-bowel-disease (263) 263
polyethylene glycols - therapeutic use (251) 251
middle aged (240) 240
immunoglobulin fab fragments - therapeutic use (239) 239
double-blind (230) 230
rheumatoid arthritis (230) 230
rheumatology (214) 214
maintenance therapy (210) 210
crohns-disease (188) 188
antibodies, monoclonal, humanized - therapeutic use (186) 186
arthritis, rheumatoid - drug therapy (186) 186
pharmacology & pharmacy (183) 183
antibodies, monoclonal, humanized (181) 181
inflammatory bowel disease (177) 177
antirheumatic agents - therapeutic use (174) 174
rheumatoid-arthritis (164) 164
etanercept (163) 163
placebo-controlled trial (148) 148
therapy (145) 145
immunosuppressive agents - therapeutic use (144) 144
ulcerative colitis (142) 142
inflammatory bowel diseases - drug therapy (141) 141
anti-inflammatory agents - therapeutic use (129) 129
certolizumab pegol - therapeutic use (126) 126
monoclonal-antibody (117) 117
ulcerative-colitis (116) 116
drug therapy (113) 113
anti-tnf (112) 112
tumor necrosis factor (112) 112
aged (111) 111
randomized-trial (107) 107
antibodies, monoclonal - adverse effects (106) 106
immunoglobulin fab fragments - adverse effects (106) 106
polyethylene glycols - adverse effects (106) 106
efficacy (104) 104
tumor-necrosis-factor (102) 102
young adult (96) 96
remission induction (95) 95
abridged index medicus (93) 93
methotrexate (93) 93
monoclonal antibodies (93) 93
necrosis-factor-alpha (93) 93
severity of illness index (93) 93
drug therapy, combination (91) 91
arthritis (88) 88
quality-of-life (88) 88
animals (87) 87
certolizumab (87) 87
safety (86) 86
antibodies, monoclonal, humanized - adverse effects (85) 85
remission (82) 82
antitumor necrosis factor (81) 81
care and treatment (81) 81
randomized controlled trials as topic (77) 77
tumor necrosis factor-alpha - immunology (77) 77
biological products - therapeutic use (75) 75
medicine, general & internal (75) 75
risk factors (75) 75
antirheumatic agents - adverse effects (72) 72
clinical trials (72) 72
golimumab (72) 72
double-blind method (71) 71
gastrointestinal agents - therapeutic use (71) 71
immunology (71) 71
health aspects (70) 70
immunosuppressive agents - adverse effects (69) 69
trial (69) 69
clinical-response (68) 68
natalizumab (67) 67
adalimumab - therapeutic use (66) 66
analysis (65) 65
biologics (65) 65
adolescent (64) 64
infliximab - therapeutic use (64) 64
methotrexate - therapeutic use (64) 64
psoriasis (64) 64
factor-alpha (63) 63
tnf inhibitors (62) 62
immunoglobulin fab fragments - administration & dosage (60) 60
polyethylene glycols - administration & dosage (60) 60
quality of life (60) 60
time factors (60) 60
medicine & public health (59) 59
retrospective studies (59) 59
rheumatoid factor (59) 59
certolizumab pegol - adverse effects (58) 58
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1092) 1092
German (21) 21
Spanish (16) 16
Russian (12) 12
Japanese (11) 11
French (9) 9
Polish (4) 4
Czech (2) 2
Hungarian (2) 2
Croatian (1) 1
Danish (1) 1
Italian (1) 1
Korean (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 08/2018, Volume 79, Issue 2, pp. 266 - 276.e5
Phase 2 psoriasis studies with the Fc-free, PEGylated, anti–tumor necrosis factor biologic certolizumab pegol demonstrated meaningful clinical activity. Assess... 
certolizumab pegol | chronic plaque psoriasis | etanercept | anti–tumor necrosis factor | CIMPACT | phase 3 trial | anti-TNF | antietumor necrosis factor | RHEUMATOID-ARTHRITIS | UNITED-STATES | TO-SEVERE PSORIASIS | MODERATE | TRIALS | METAANALYSIS | EFFICACY | ADALIMUMAB | SAFETY | PREVALENCE | DERMATOLOGY | Etanercept | Analysis | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2007, Volume 357, Issue 3, pp. 228 - 238
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2007, Volume 357, Issue 3, pp. 239 - 250
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 06/2009, Volume 68, Issue 6, pp. 805 - 811
Journal Article
Journal Article
Rheumatology (Oxford, England), ISSN 1462-0324, 2017, Volume 56, Issue 9, pp. 1498 - 1509
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 06/2009, Volume 68, Issue 6, pp. 797 - 804
Background: Certolizumab pegol is a PEGylated tumour necrosis factor inhibitor. Objective: To evaluate the efficacy and safety of certolizumab pegol versus... 
TUMOR-NECROSIS-FACTOR | THERAPY | CROHNS-DISEASE | FUNCTIONAL-CAPACITY | PHASE-III | RECEIVING CONCOMITANT METHOTREXATE | MONOCLONAL-ANTIBODY | TNF-ALPHA | RHEUMATOLOGY | INFLIXIMAB | DISEASE-ACTIVITY | Certolizumab Pegol | Follow-Up Studies | Humans | Immunoglobulin Fab Fragments - adverse effects | Immunosuppressive Agents - therapeutic use | Polyethylene Glycols - adverse effects | Male | Immunoglobulin Fab Fragments - therapeutic use | Methotrexate - therapeutic use | Polyethylene Glycols - therapeutic use | Arthritis, Rheumatoid - diagnostic imaging | Antibodies, Monoclonal, Humanized | Arthritis, Rheumatoid - drug therapy | Tumor Necrosis Factor-alpha - immunology | Adult | Female | Drug Therapy, Combination | Immunosuppressive Agents - administration & dosage | Double-Blind Method | Drug Administration Schedule | Treatment Outcome | Polyethylene Glycols - administration & dosage | Immunoglobulin Fab Fragments - administration & dosage | Blood Coagulation - drug effects | Antibodies, Monoclonal - administration & dosage | Arthrography | Immunosuppressive Agents - adverse effects | Methotrexate - administration & dosage | Arthritis, Rheumatoid - immunology | Usage | Rheumatoid arthritis | Patient outcomes | Dosage and administration | Methotrexate | Drug therapy | Health aspects | TNF inhibitors | Tumor necrosis factor-TNF | Immunoglobulins | Quality of life | Index Medicus
Journal Article
Annals of the rheumatic diseases, ISSN 0003-4967, 2014, Volume 73, Issue 1, pp. 39 - 47
Journal Article